Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer

Romana Moench, Tanja Grimmig, Vinicius Kannen, Sudipta Tripathi, Marc Faber, Eva-Maria Moll, Anil Chandraker, Reinhard Lissner, Christoph-Thomas Germer, Ana Maria Waaga-Gasser (Corresponding Author), Martin Gasser (Corresponding Author)

Research output: Contribution to journalArticle

16 Citations (Scopus)
4 Downloads (Pure)

Abstract

Platelet-derived growth factor (PDGF) and signaling via its receptors plays a crucial role in tumor cell proliferation and thus may represent an attractive target besides VEGF/EGFR-based antibody therapies. In this study we analyzed the influence of PDGF in colorectal cancer. PDGF was expressed intensively in early and even more intensively in late stage primary CRCs. Like VEGF, PDGF enhanced human colon cancer proliferation, and increased oxidative glycolytic activity, and activated HIF1α and c-Myc in vitro. PDGF activated the PI3K/Akt/mTOR pathway while leaving MAPK signaling untouched. Further dissection showed that inhibition of Akt strongly impeded cancer cell growth while inhibition of PI3K did not. MAPK analysis suggested an inhibitory crosstalk between both pathways, thus explaining the different effects of the Akt and PI3K inhibitors on cancer cell proliferation. PDGF stimulates colon cancer cell proliferation, and prevents inhibitor induced apoptosis, resulting in tumor growth. Therefore inhibition of PDGF signaling seems to be a promising target in colorectal cancer therapy. However, due to the multifaceted nature of the intracellular PDGF signaling, careful intervention strategies are needed when looking into specific signaling pathways like PI3K/Akt/mTOR and MAPK.

Original languageEnglish
Pages (from-to)68749-68767
Number of pages19
JournalOncotarget
Volume7
Issue number42
DOIs
Publication statusPublished - 8 Sep 2016

Fingerprint

Platelet-Derived Growth Factor
Glycolysis
Phosphatidylinositol 3-Kinases
Colorectal Neoplasms
Cell Proliferation
Colonic Neoplasms
Vascular Endothelial Growth Factor A
Neoplasms
Growth
Dissection
Apoptosis
Antibodies
Therapeutics

Keywords

  • PDGF
  • colorectal cancer
  • PI3K/Akt/mTOR
  • MAPK pathway
  • glucose metabolism

Cite this

Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. / Moench, Romana; Grimmig, Tanja; Kannen, Vinicius; Tripathi, Sudipta; Faber, Marc; Moll, Eva-Maria; Chandraker, Anil; Lissner, Reinhard; Germer, Christoph-Thomas; Waaga-Gasser, Ana Maria (Corresponding Author); Gasser, Martin (Corresponding Author).

In: Oncotarget, Vol. 7, No. 42, 08.09.2016, p. 68749-68767.

Research output: Contribution to journalArticle

Moench, R, Grimmig, T, Kannen, V, Tripathi, S, Faber, M, Moll, E-M, Chandraker, A, Lissner, R, Germer, C-T, Waaga-Gasser, AM & Gasser, M 2016, 'Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer' Oncotarget, vol. 7, no. 42, pp. 68749-68767. https://doi.org/10.18632/oncotarget.11899
Moench, Romana ; Grimmig, Tanja ; Kannen, Vinicius ; Tripathi, Sudipta ; Faber, Marc ; Moll, Eva-Maria ; Chandraker, Anil ; Lissner, Reinhard ; Germer, Christoph-Thomas ; Waaga-Gasser, Ana Maria ; Gasser, Martin. / Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. In: Oncotarget. 2016 ; Vol. 7, No. 42. pp. 68749-68767.
@article{40626402a04c45a0a1c1782c5f252353,
title = "Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer",
abstract = "Platelet-derived growth factor (PDGF) and signaling via its receptors plays a crucial role in tumor cell proliferation and thus may represent an attractive target besides VEGF/EGFR-based antibody therapies. In this study we analyzed the influence of PDGF in colorectal cancer. PDGF was expressed intensively in early and even more intensively in late stage primary CRCs. Like VEGF, PDGF enhanced human colon cancer proliferation, and increased oxidative glycolytic activity, and activated HIF1α and c-Myc in vitro. PDGF activated the PI3K/Akt/mTOR pathway while leaving MAPK signaling untouched. Further dissection showed that inhibition of Akt strongly impeded cancer cell growth while inhibition of PI3K did not. MAPK analysis suggested an inhibitory crosstalk between both pathways, thus explaining the different effects of the Akt and PI3K inhibitors on cancer cell proliferation. PDGF stimulates colon cancer cell proliferation, and prevents inhibitor induced apoptosis, resulting in tumor growth. Therefore inhibition of PDGF signaling seems to be a promising target in colorectal cancer therapy. However, due to the multifaceted nature of the intracellular PDGF signaling, careful intervention strategies are needed when looking into specific signaling pathways like PI3K/Akt/mTOR and MAPK.",
keywords = "PDGF, colorectal cancer, PI3K/Akt/mTOR, MAPK pathway, glucose metabolism",
author = "Romana Moench and Tanja Grimmig and Vinicius Kannen and Sudipta Tripathi and Marc Faber and Eva-Maria Moll and Anil Chandraker and Reinhard Lissner and Christoph-Thomas Germer and Waaga-Gasser, {Ana Maria} and Martin Gasser",
note = "We thank Mrs. Nadine Rhodes, Mrs. Sabine Mueller-Morath, and Mrs. Mariola Dragan for their excellent technical assistance as well as Mrs. Ingrid Strauss and Mrs. Ulrike Faber. We also thank Mrs. and Mr. Dr. Sommer for their expertise in the oxygen measurement.",
year = "2016",
month = "9",
day = "8",
doi = "10.18632/oncotarget.11899",
language = "English",
volume = "7",
pages = "68749--68767",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "42",

}

TY - JOUR

T1 - Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer

AU - Moench, Romana

AU - Grimmig, Tanja

AU - Kannen, Vinicius

AU - Tripathi, Sudipta

AU - Faber, Marc

AU - Moll, Eva-Maria

AU - Chandraker, Anil

AU - Lissner, Reinhard

AU - Germer, Christoph-Thomas

AU - Waaga-Gasser, Ana Maria

AU - Gasser, Martin

N1 - We thank Mrs. Nadine Rhodes, Mrs. Sabine Mueller-Morath, and Mrs. Mariola Dragan for their excellent technical assistance as well as Mrs. Ingrid Strauss and Mrs. Ulrike Faber. We also thank Mrs. and Mr. Dr. Sommer for their expertise in the oxygen measurement.

PY - 2016/9/8

Y1 - 2016/9/8

N2 - Platelet-derived growth factor (PDGF) and signaling via its receptors plays a crucial role in tumor cell proliferation and thus may represent an attractive target besides VEGF/EGFR-based antibody therapies. In this study we analyzed the influence of PDGF in colorectal cancer. PDGF was expressed intensively in early and even more intensively in late stage primary CRCs. Like VEGF, PDGF enhanced human colon cancer proliferation, and increased oxidative glycolytic activity, and activated HIF1α and c-Myc in vitro. PDGF activated the PI3K/Akt/mTOR pathway while leaving MAPK signaling untouched. Further dissection showed that inhibition of Akt strongly impeded cancer cell growth while inhibition of PI3K did not. MAPK analysis suggested an inhibitory crosstalk between both pathways, thus explaining the different effects of the Akt and PI3K inhibitors on cancer cell proliferation. PDGF stimulates colon cancer cell proliferation, and prevents inhibitor induced apoptosis, resulting in tumor growth. Therefore inhibition of PDGF signaling seems to be a promising target in colorectal cancer therapy. However, due to the multifaceted nature of the intracellular PDGF signaling, careful intervention strategies are needed when looking into specific signaling pathways like PI3K/Akt/mTOR and MAPK.

AB - Platelet-derived growth factor (PDGF) and signaling via its receptors plays a crucial role in tumor cell proliferation and thus may represent an attractive target besides VEGF/EGFR-based antibody therapies. In this study we analyzed the influence of PDGF in colorectal cancer. PDGF was expressed intensively in early and even more intensively in late stage primary CRCs. Like VEGF, PDGF enhanced human colon cancer proliferation, and increased oxidative glycolytic activity, and activated HIF1α and c-Myc in vitro. PDGF activated the PI3K/Akt/mTOR pathway while leaving MAPK signaling untouched. Further dissection showed that inhibition of Akt strongly impeded cancer cell growth while inhibition of PI3K did not. MAPK analysis suggested an inhibitory crosstalk between both pathways, thus explaining the different effects of the Akt and PI3K inhibitors on cancer cell proliferation. PDGF stimulates colon cancer cell proliferation, and prevents inhibitor induced apoptosis, resulting in tumor growth. Therefore inhibition of PDGF signaling seems to be a promising target in colorectal cancer therapy. However, due to the multifaceted nature of the intracellular PDGF signaling, careful intervention strategies are needed when looking into specific signaling pathways like PI3K/Akt/mTOR and MAPK.

KW - PDGF

KW - colorectal cancer

KW - PI3K/Akt/mTOR

KW - MAPK pathway

KW - glucose metabolism

U2 - 10.18632/oncotarget.11899

DO - 10.18632/oncotarget.11899

M3 - Article

VL - 7

SP - 68749

EP - 68767

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 42

ER -